Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00007611-194806000-00009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Loss of FTH1 Induces Ferritinophagy-Mediated Ferroptosis in Anaemia of Myelodysplastic Syndromes.
J Cell Mol Med
January 2025
Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
Single-cell sequencing of lineage negative (Lin-) cells from patients with myelodysplastic syndromes (MDS) revealed a reduction in ferritin heavy chain 1 (FTH1) levels, yet the significance of this decrease in FTH1 in the pathophysiology of MDS remains unclear. In this study, we evaluated the role of FTH1 in patients with MDS. The mRNA expression of FTH1 in GlycoA nucleated erythrocytes from MDS patients was significantly lower than that in control group.
View Article and Find Full Text PDFDisease foci of pharmaceutical research and development as reflected in applications for International Nonproprietary Names, 1953-2022.
Bull World Health Organ
January 2025
INN Programme and Classification of Medical Products, World Health Organization, 20 Avenue Appia, 1211Geneva, Switzerland.
Objective: To evaluate trends in pharmaceutical research and development, and to correlate these trends with global medical need.
Methods: We obtained details of proposed pharmaceutical substances from 1953 to 2022 from the International Nonproprietary Names (INN) database. We used the DrugBank and Cortellis databases to obtain the INN included in approved medicines over the same period.
Feasibility and effectiveness of the prolonged use of eltrombopag in addition to immunosuppression in patients with acquired aplastic anemia: a single-center real-life experience.
Platelets
December 2024
Hematology and Transplantation Unit, IRCCS San Gerardo Hospital, Monza, Italy.
Acquired Aplastic Anemia (AAA) is a rare disease involving primary bone marrow failure with consequent pancytopenia. The addition of the synthetic thrombopoietin-receptor agonist eltrombopag (ELT) to standard immunosuppression for the treatment of AAA has led to improvements in hemopoietic outcomes of AAA. Most of the data on the use of ELT for AAA was based on a maximum of 6 months of therapy.
View Article and Find Full Text PDFReduction of HLA antibodies by bi-specific antibody blinatumomab.
Hum Immunol
November 2024
HLA and Immunogenetics Laboratory, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States. Electronic address:
Donor specific antibodies against human leukocyte antigen (HLA) can cause engraftment failure in hemopoietic stem cell transplantation, or antibody mediated rejection in solid organ transplantation. To increase the chance of successful transplants, donor specific antibodies have to be reduced or depleted in patients with high levels of HLA antibodies. However, no current therapies have been proven to remove or reduce HLA antibodies effectively in the majority of patients.
View Article and Find Full Text PDFCellular and Immunological Analysis of 2D2/Th Hybrid Mice Prone to Experimental Autoimmune Encephalomyelitis in Comparison with 2D2 and Th Lines.
Int J Mol Sci
September 2024
Institute of Chemical Biology and Fundamental Medicine of the Siberian Division of RAS, Lavrentiev Ave. 8, Novosibirsk 630090, Russia.
Previously, we described the mechanisms of development of autoimmune encephalomyelitis (EAE) in 3-month-old C57BL/6, Th, and 2D2 mice. The faster and more profound spontaneous development of EAE with the achievement of deeper pathology occurs in hybrid 2D2/Th mice. Here, the cellular and immunological analysis of EAE development in 2D2/Th mice was carried out.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!